长链非编码RNA（lncRNA）具有治疗靶向治疗多种疾病的潜力，包括癌症。在过去的十年中，已有几种基于RNA的治疗药物（ASO和小干扰RNA）获得了FDA的批准。凭借其强效作用，基于lncRNA的治疗药物具有新兴的重要意义。一个重要的lncRNA靶点是LINC-PINT，其具有普遍的功能并与著名的肿瘤抑制基因TP53有关。与p53相似，LINC-PINT的肿瘤抑制活性与癌症进展有关。此外，LINC-PINT的几个分子靶点直接或间接用于常规临床实践。我们进一步将LINC-PINT与结肠腺癌的免疫反应联系起来，提出LINC-PINT作为免疫检查点抑制剂的新型生物标志物的潜在效用。总的来说，目前的证据表明LINC-PINT可考虑用作癌症和其他多种疾病的诊断/预后标志物。版权所有©2023 Bukhari、Khan、Li、Swiatczak、Thorne、Zheng和Mi。

Long noncoding RNAs (lncRNAs) possess the potential for therapeutic targeting to treat many disorders, including cancers. Several RNA-based therapeutics (ASOs and small interfering RNAs) have gained FDA approval over the past decade. And with their potent effects, lncRNA-based therapeutics are of emerging significance. One important lncRNA target is LINC-PINT, with its universalized functions and relationship with the famous tumor suppressor gene TP53. Establishing clinical relevance, much like p53, the tumor suppressor activity of LINC-PINT is implicated in cancer progression. Moreover, several molecular targets of LINC-PINT are directly or indirectly used in routine clinical practice. We further associate LINC-PINT with immune responses in colon adenocarcinoma, proposing the potential utility of LINC-PINT as a novel biomarker of immune checkpoint inhibitors. Collectively, current evidence suggests LINC-PINT can be considered for use as a diagnostic/prognostic marker for cancer and several other diseases.Copyright © 2023 Bukhari, Khan, Li, Swiatczak, Thorne, Zheng and Mi.